1 Answers
This combination is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.This combination is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
Sabitar Tablet সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে Sabitar
4769 views
Answered